Market Access

Next-Generation Forecasting Must Account for Payer Controls

The market access landscape for pharmaceutical products has shifted as payers struggle to control ...

Accelerating Appropriate Access to Therapy with Centralized Patient Support

Rising patient financial obligations have led to increased patient consumerism, changing the game for ...

Are We Reaching the End of the Line for PBM Exclusion Lists?

In the rapidly evolving U.S. healthcare landscape, the pharmacy benefit manager (PBM) exclusion lists ...

Common Pitfalls to Avoid to Ensure a Successful Product Launch

After spending millions on R&D just to get a product to market—and millions more ...

What Trump’s Win Might Mean for Pharma

First, let’s acknowledge the obvious—nobody knows what Trump’s win might mean for the pharma ...

The Promise and Threat of Biosimilars

The number of biologics available in the U.S. has grown every year for the ...

The Value Crisis in Pharma

The core of pharmaceutical marketing has expanded from efficacy and safety to include value. ...

Maximize Your Brand’s Value Post Patent Expiration Through Authorized Generics

In today’s marketplace, biopharmaceutical companies face numerous challenges from cost containment to patent expiration.1 ...

Novartis Strikes Pay-for-Performance Deals for Heart-Failure Drug Entresto

When Novartis’ new heart-failure treatment Entresto was approved in July, the pharmaceutical company said ...